YG-01 / YGION Biomedical - LARVOL DELTA

YGION Biomedical Awarded Grant from the Austrian Research Promotion Agency to develop Individualized Cancer Immunotherapies (YGION Biomedical Press Release) - "YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer immunotherapies, today announces further fundraising news with the award of a significant Life Sciences grant from the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft; FFG). This non-dilutive funding will be used over the next 12 months to further development YGION’s unique YGNITE technology platform and support preclinical development of YGION’s lead program, YG-01....This grant is a follow up to YGION’s recent announcement of a €15 million Series A financing round from an Austrian private trust. This competitive grant is awarded to life science companies to support the research and development for innovative healthcare products in Austria."

Financing • Oncology

YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies (PRNewswire) - "YGION Biomedical GmbH...today announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION's unique YGNITETM technology platform and advance the lead program YG-01 into preclinical and clinical development."

Financing • Oncology